DBL Dobutamine Injection

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Dobutamine hydrochloride

Available from:

Hospira Australia Pty Ltd

Class:

Medicine Listed (Export Only)

Patient Information leaflet

 
DBL
™
 Dobutamine Hydrochloride Injection CMI

Page  1

DBL
™ 
DOBUTAMINE HYDROCHLORIDE 
INJECTION
_ _ 

Dobutamine Hydrochloride  (_do-BEWT-a-meen)_
_ _

CONSUMER MEDICINE INFORMATION

_Date of Dispensing _
_Consumer Name _
_Pharmacist Name _
_Consumer Address _
_Pharmacist Address _

_ _
WHAT IS IN THIS LEAFLET 

This leaflet answers some 
common questions about DBL
™ 
Dobutamine Hydrochloride 
Injection. 

It does not contain all the 
available information. 

It does not take the place of 
talking to your doctor or 
pharmacist. 

All medicines have risks and 
benefits.  Your doctor has 
weighed the risks of you being 
given DBL
™ 
Dobutamine 
Hydrochloride Injection against 
the benefits they expect it will 
have for you. 

IF YOU HAVE ANY CONCERNS ABOUT 
BEING GIVEN THIS MEDICINE, ASK 
YOUR DOCTOR OR PHARMACIST. 

KEEP THIS LEAFLET IN A SAFE PLACE. 
You may need to read it again. 

WHAT DBL
™ 
DOBUTAMINE 
HYDROCHLORIDE 
INJECTION IS USED FOR 

DBL
™ 
Dobutamine Hydrochloride 
Injection is used in patients who 
require short-term treatment of 
heart failure following a heart 
attack or heart surgery. 

DBL
™ 
Dobutamine Hydrochloride 
Injection acts directly on the heart 
muscle to increase the force of 
each contraction. 

Your doctor may have prescribed 
this medicine for another reason.   

ASK YOUR DOCTOR IF YOU HAVE 
ANY QUESTIONS ABOUT WHY DBL
™ 
DOBUTAMINE HYDROCHLORIDE 
INJECTION HAS BEEN PRESCRIBED 
FOR YOU. 

There is no evidence that DBL
™ 
Dobutamine Hydrochloride 
Injection is addictive. 

This medicine is available only 
with a doctor’s prescription. 

BEFORE YOU ARE GIVEN 
DBL
™ 
DOBUTAMINE 
HYDROCHLORIDE 
INJECTION 

_WHEN YOU MUST NOT BE _
_GIVEN IT _

YOU MUST NOT BE GIVEN DBL
™ 
DOBUTAMINE HYDROCHLORIDE 
INJECTION IF YOU HAVE AN ALLERGY 
TO DOBUTAMINE OR ANY OF THE 
INGREDIENTS LISTED AT THE END OF 
THIS LEAFLET. 

Symptoms of an alle

Summary of Product characteristics

Product Information – Australia 

Version 4.0 

Page 1 
DBL
™
 DOBUTAMINE HYDROCHLORIDE INJECTION 

NAME OF THE MEDICINE 
Dobutamine hydrochloride 

N
OH
.

HCl
CH
3
H
HO
HO

C
18
H
25
NO
3
.HCl 

MW = 337.9, CAS REGISTRY NO: - 49745-95-1  

(_RS_)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-ethyl]
benzene-1,2-diol hydrochloride 

DESCRIPTION 
Dobutamine hydrochloride is a white to practically white, crystalline
powder. It is sparingly soluble in 
water and methyl alcohol; soluble in alcohol. Dobutamine is
incompatible with alkaline solutions such 
as sodium bicarbonate 5%. 

DBL
™
 Dobutamine Hydrochloride Injection is a sterile solution containing
in each 20 mL vial, 
Dobutamine Hydrochloride USP 280.2 mg (250 mg Dobutamine equivalent)
and Sodium Metabisulfite 
BP 4.4 mg. 

PHARMACOLOGY 
Dobutamine hydrochloride is an inotropic agent whose primary activity
results from stimulation of the 
beta receptors of the heart while producing comparatively mild
chronotropic, hypertensive, 
arrhythmogenic and vasodilative effects. The drug is believed to be a
direct agonist which, in animal 
studies, produces less increase in heart rate and less decrease in
peripheral vascular resistance for a 
given inotropic effect than does isoprenaline. 

In patients with depressed cardiac function, both dobutamine and
isoprenaline increase the cardiac 
output to a similar degree. In the case of dobutamine, this increase
is usually not accompanied by 
marked increases in heart rate (although tachycardia is occasionally
observed), and the cardiac 
stroke volume is usually increased. In contrast, isoprenaline
increases the cardiac index primarily by 
increasing the heart rate while stroke volume changes little or
declines. 

Facilitation of atrioventricular conduction has been observed in human
electrophysiologic studies in 
normal subjects and in patients with atrial fibrillation. 

Systemic vascular resistance is usually decr